Experience in using Аntistax® in patients with lower limb chronic venous insufficiency and accompanying arterial hypertension
Abstract
The main pathogenetic causes of the development of lower limb chronic venous insufficiency (CVI) are associated with hypertension in the inferior vena cava, venous stasis, and ischaemia of the vascular wall. Alterations in microcirculation responsible for the metabolic and trophic processes of the venous wall appear on the background of change in the macrocirculatory bed. A considerable role of the venous endothelial dysfunction was noted. Prescription of phleboprotectors and phlebotonics is of fundamental importance. Efficacy of Antistax makes it possible to recommend its use in combined therapy of various-aetiology and various-grade CVI.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.